Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
This study has been terminated.
Study NCT00038376 Information provided by M.D. Anderson Cancer Center
First Received: May 30, 2002 Last Updated: March 12, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, T-Cell
Mycosis Fungoides
Hematologic Neoplasms
Additional conditions recognized in this trial
Lymphoma
Mycoses
Neoplasms
Sezary Syndrome
More general conditions related to this trial
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell, Cutaneous
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Interventions listed in this trial
Isotretinoin (Accutane)
Interferon Alpha
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Alfa-2b
Interferon Type I, Recombinant
Interferon-alpha
Interferons
Isotretinoin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Dermatologic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Back to top of Main Content
